# US 2025/0367141 A1 · Methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367141 A1
- Document ID: US20250367141A1
- Status: Published application
- Kind: A1
- Application number: 19/302,585
- Filed: 2025-08-18
- Published: 2025-12-04
- Earliest claimed: 2015-04-29
- Assignees: Radius Pharmaceuticals, Inc.
- Applicants: Radius Pharmaceuticals, Inc.
- Inventors: Fiona GARNER; Gary Hattersley
- Web page: https://patentgrep.com/patent/US20250367141A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure: or a salt or solvate thereof.

## Claims

### Claim 1

A method of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer comprising administering to said subject a therapeutically effective amount of RAD1901 having the structure:
or a salt or solvate thereof.

### Claim 2

A method of inhibiting tumor growth or producing tumor regression in a subject having a mutant estrogen receptor alpha positive cancer comprising administering to said subject a therapeutically effective amount of RAD1901 having the structure:
or a salt or solvate thereof.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, and pituitary cancer.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is a metastatic cancer.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein said cancer is positive for the mutant estrogen receptor alpha comprising one or more mutations selected from the group consisting of Y537X1, L536X2, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein:
X1 is S, N, or C, D538G; and X2 is R or Q,

### Claim 6 (depends on 5)

The method of claim 5, wherein the mutation is Y537S.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the ratio of the concentration of RAD1901 or a salt or solvate thereof in the tumor to the concentration of RAD1901 or a salt or solvate thereof in plasma (T/P) following administration is at least about 15.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein subject has osteoporosis or a high risk of osteoporosis.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject is a pre-menopausal woman.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject is a post-menopausal woman who had relapsed or progressed after previous treatment with SERMs and/or AIs.

### Claim 11 (depends on 1, 2)

The method of claim 1 or 2, wherein the therapeutically effective amount is about 150 to about 1,500 mg q.d.

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2, wherein the salt thereof is RAD1901 dihydrochloride.

### Claim 13 (depends on 1, 2)

The method of claim 1 or 2, wherein the tumor is resistant to a drug selected from the group consisting of anti-estrogens, aromatase inhibitors, and combinations thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the anti-estrogen is tamoxifen or fulvestrant.

### Claim 15 (depends on 13)

The method of claim 13, wherein the aromatase inhibitor is aromasin.

### Claim 16 (depends on 1, 2)

The method of claim 1 or 2, wherein the therapeutically effective amount is 150 mg to 2,000 mg.

### Claim 17 (depends on 16)

The method of claim 16, wherein the therapeutically effective amount is 200 mg, 400 mg, or 500 mg.
